SANUWAVE Q2 revenue $7.2M (+53% YoY); guides Q3 growth 65-75%

SANUWAVE Health, Inc.

2024-Q2 EPS reported $0.00 revenue$12,948,000

Q2 revenue $7.2M, up 53% YoY; 72 UltraMist systems sold vs 49 in Q2 2023.
GAAP operating income $2.0M; net income $6.6M vs loss $7.3M YoY.
Adjusted EBITDA $1.5M vs $171K YoY; year-to-date $1.4M vs -$1.6M.
Q3 2024 revenue guidance $8-8.5M (65-75% growth); gross margin mid 70s.
Reverse stock split approved, note/warrant exchange fully subscribed to simplify cap structure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.